A Phase 3 Study Of SU011248 In Combination With Paclitaxel Versus Bevacizumab With Paclitaxel In The First-Line Advanced Disease Setting In Patients Having Breast Cancer.

Trial Profile

A Phase 3 Study Of SU011248 In Combination With Paclitaxel Versus Bevacizumab With Paclitaxel In The First-Line Advanced Disease Setting In Patients Having Breast Cancer.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 07 Sep 2012

At a glance

  • Drugs Bevacizumab; Paclitaxel; Sunitinib
  • Indications Advanced breast cancer
  • Focus Biomarker; Registrational; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 Jun 2011 Planned end date changed from 1 Jun 2011 to 1 Aug 2011 as reported by ClinicalTrials.gov.
    • 19 Jan 2011 Planned end date changed from 1 Jan 2011 to 1 Jun 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top